Vor Bio Reports 48-Week gMG Data: 42% Reached MSE
Vor Bio reported post hoc 48-week data from a China Phase 3 gMG study of telitacicept: 42% reached minimal symptom expression at any time; >94% had ≥5-point MG-ADL improvement. Most MSE events were sustained at the next monthly check.Material DetailsContext by AI AnalystThis extends previously shar…